Success Stories
Highlights of the PCI news focused on Penn commercialization accomplishments
Interius BioTherapeutics Receives Clearance to Begin Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
Interius intends to begin patient enrollment for the trial in the fourth quarter of 2024.
Development of RNA Therapeutics Targets Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.
Cabaletta’s Early Data Shows Potential for Treating Autoimmune Diseases
The company reported positive results in the first two patients who received its new CAR T therapy, CABA-201, which aims to treat the autoimmune diseases lupus and myositis.
Nature Interviews Penn Medicine’s AI Leader César de La Fuente
César de la Fuente, PhD, Presidential Assistant Professor at Penn, has significantly advanced the field of antibiotic discovery through his innovative use of computational and AI-assisted techniques.
Four Penn Startups Make The Philadelphia Business Journal’s PHL Inno List of 2024 Startups to Watch
Baleena, BlueWhale Bio, Treeswift and Verismo were all recognized.
PCI Recognized on Technical.ly’s List of Philadelphia’s Biggest Tech Moments of 2023
In the article, Technical.ly highlights that Penn affiliated startups attracted over $1 billion in investment capital in 2023.
ViTToria Biotherapeutics Secures $15M
ViTToria is focused on developing novel CAR-T cell therapies that transcend the limitations of current cell therapies.
Heirloom Opens First Commercial Carbon Capture Plant in the U.S.
Heirloom uses a process called direct air capture to remove greenhouse gases from the atmosphere.
Penn spinout Interius Biotherapeutics raises another $21.5M
Co-founded by Saar Gill, MD, PhD, Interius is developing a new platform for cell-specific gene delivery in patients.
PCI Recognized In Clinical Leader Article about How Academic Medical Centers Can Capture Greater Value In The Cell & Gene Therapy Industry
The Penn Center of Innovation was recognized in an article in Clinical Leader about how academic medical centers can leverage their unique advantages to develop and deliver cell and gene therapies.